PBI-MST-01(NCT04541108) Substudy TAK-02: Intratumoral Microdosing of TAK-676 in HNSCC
Status:
Completed
Trial end date:
2022-11-15
Target enrollment:
Participant gender:
Summary
This is a multi-center, open-label Phase 0 substudy designed to study the localized
pharmacodynamics (PD) of TAK-676 alone or in combination with Carboplatin, 5-FU, or
Paclitaxel within the tumor microenvironment (TME) when administered intratumorally in
microdose quantities via the CIVO device in patients diagnosed with Head and Neck Squamous
Cell Carcinoma presenting with a surface accessible solid tumor for which there is a
scheduled surgical intervention. This substudy is a cohort of the PBI-MST-01 Master Protocol.